Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
This grant supports a network to conduct and coordinate canine cancer immunotherapy trials, advancing treatments for both pet dogs and humans by leveraging shared disease characteristics.
Funder: National Institutes of Health
Due Dates (Anticipated): January 2027
Funding Amounts: Five U01 cooperative agreements anticipated; specific award size not stated; multi-year support expected.
Summary: Supports canine cancer immunotherapy clinical trials and network coordination to inform and advance human cancer treatments.
Description
This opportunity aims to advance cancer immunotherapy research by supporting clinical trials in pet dogs with spontaneously occurring cancers, leveraging their similarities to human disease progression and treatment response. The program will fund a network (K9CIN) consisting of five U01 cooperative agreements: one Network Coordinating Center (with limited research activities) and four sites conducting canine clinical trials using immunotherapeutic agents alone or in combination with other treatments. The results are intended to inform both canine health and translational research for human cancer therapies. This reissue consolidates previous funding mechanisms to streamline support for the network and encourages applications for both the coordinating center and clinical trial sites.
